All Stories

  1. A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

    Article • Clinical Cancer Research, September 2020, American Association for Cancer Research (AACR)

    Laia Pare

  2. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Article • Clinical Cancer Research, September 2020, American Association for Cancer Research (AACR)

    Laia Pare

  3. DNA methylation events in transcription factors and gene expression changes in colon cancer

    Article • Epigenomics, September 2020, Future Medicine

    Laia Pare

  4. PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.

    Article • Clinical Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Laia Pare

  5. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

    Article • Cancers, July 2020, MDPI AG

    Laia Pare

  6. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Article • Nature Communications, January 2020, Springer Science + Business Media

    Laia Pare

  7. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

    Article • The Lancet Oncology, January 2020, Elsevier

    Laia Pare

  8. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    Article • Frontiers in Oncology, September 2019, Frontiers

    Laia Pare

  9. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Article • September 2019, Springer Science + Business Media

    Laia Pare

  10. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    Article • Frontiers in Oncology, August 2019, Frontiers

    Laia Pare

  11. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

    Article • Molecular Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Laia Pare

  12. Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2

    Article • The Oncologist, July 2019, Wiley

    Laia Pare

  13. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

    Article • International Journal of Cancer, June 2019, Wiley

    Laia Pare

  14. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

    Article • Cancer Research, June 2019, American Association for Cancer Research (AACR)

    Laia Pare

  15. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

    Article • Annals of Oncology, June 2019, Elsevier

    Laia Pare

  16. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

    Article • JNCI Journal of the National Cancer Institute, April 2019, Oxford University Press (OUP)

    Laia Pare

  17. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Article • Frontiers in Oncology, April 2019, Frontiers

    Laia Pare

  18. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

    Article • BMC Medicine, January 2019, Springer Science + Business Media

    Laia Pare

  19. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Article • Annals of Oncology, October 2018, Elsevier

    Laia Pare

  20. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

    Article • Annals of Oncology, January 2018, Elsevier

    Laia Pare

  21. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma

    Article • Cell Reports, November 2017, Elsevier

    Laia Pare

  22. Corrigendum re: “TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer” [Eur Urol 2016;70:709–13]

    Article • European Urology, August 2017, Elsevier

    Laia Pare

  23. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

    Article • Cancer Research, May 2017, American Association for Cancer Research (AACR)

    Laia Pare

  24. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Article • Stem Cell Reports, May 2017, Elsevier

    Laia Pare

  25. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

    Article • The Lancet Oncology, April 2017, Elsevier

    Laia Pare

  26. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

    Article • Cancer Research, March 2017, American Association for Cancer Research (AACR)

    Laia Pare

  27. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

    Article • Oncotarget, February 2017, Impact Journals, LLC

    Laia Pare

  28. Identification of ALK , ROS1 , and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non–Small-Cell Lung Cancer ...

    Article • Clinical Chemistry, January 2017, AACC

    Dr Crisitna Teixidó, Fernando Lopez-Rios, Laia Pare

  29. A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

    Article • Clinical Cancer Research, November 2016, American Association for Cancer Research (AACR)

    Laia Pare

  30. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer

    Article • European Urology, November 2016, Elsevier

    Laia Pare

  31. Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

    Article • JAMA Oncology, October 2016, American Medical Association (AMA)

    Laia Pare

  32. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

    Article • Annals of Oncology, October 2016, Elsevier

    Laia Pare

  33. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

    Article • BMC Medicine, December 2015, Springer Science + Business Media

    Laia Pare

  34. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer

    Article • Bioinformatics, November 2015, Oxford University Press (OUP)

    Dr Benjamin Haibe-Kains, Laia Pare

  35. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer

    Article • Clinical Epigenetics, July 2015, Springer Science + Business Media

    Lisardo Bosca, Laia Pare

  36. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design

    Article • Gaceta Sanitaria, July 2015, Elsevier

    Dr Jesus Almeda, Laia Pare

  37. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer

    Article • Journal of Thoracic Oncology, July 2015, Elsevier

    Laia Pare

  38. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer

    Article • Clinical Cancer Research, June 2015, American Association for Cancer Research (AACR)

    Laia Pare

  39. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy

    Article • The Pharmacogenomics Journal, February 2015, Springer Science + Business Media

    Laia Pare

  40. Large differences in global transcriptional regulatory programs of normal and tumor colon cells

    Article • BMC Cancer, September 2014, Springer Science + Business Media

    Laia Pare

  41. Identification of candidate susceptibility genes for colorectal cancer through eQTL analysis

    Article • Carcinogenesis, April 2014, Oxford University Press (OUP)

    Laia Pare

  42. Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer

    Article • Molecular Cancer, January 2014, Springer Science + Business Media

    Laia Pare

  43. Discovery and Functional Assessment of Gene Variants in the Vascular Endothelial Growth Factor Pathway

    Article • Human Mutation, November 2013, Wiley

    Laia Pare

  44. Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan

    Article • The Pharmacogenomics Journal, August 2013, Springer Science + Business Media

    Laia Pare

  45. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region

    Article • Pharmacogenetics and Genomics, March 2013, Wolters Kluwer Health

    Laia Pare

  46. Pharmacogenetic analysis in the treatment of Hodgkin lymphoma

    Article • Leukemia & Lymphoma, February 2013, Taylor & Francis

    Laia Pare

  47. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

    Article • The Pharmacogenomics Journal, February 2012, Springer Science + Business Media

    Fernando Fernández-Bañares, Prof. Luis Rodrigo, Laia Pare

  48. Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2011, Elsevier

    Laia Pare

  49. A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

    Article • British Journal of Cancer, June 2011, Springer Science + Business Media

    Laia Pare

  50. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

    Article • Cancer Science, August 2010, Wiley

    Laia Pare

  51. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy

    Article • British Journal of Clinical Pharmacology, April 2010, Wiley

    Laia Pare

  52. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil

    Article • Journal of Cancer Research and Clinical Oncology, February 2010, Springer Science + Business Media

    Laia Pare

  53. Erratum: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

    Article • British Journal of Cancer, April 2009, Springer Science + Business Media

    Laia Pare

  54. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

    Article • Breast Cancer Research and Treatment, February 2009, Springer Science + Business Media

    Laia Pare

  55. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

    Article • British Journal of Cancer, September 2008, Springer Science + Business Media

    Laia Pare

  56. Methylenetetrahydrofolate Reductase Gene Polymorphisms: Genomic Predictors of Clinical Response to Fluoropyrimidine-Based Chemotherapy in Females

    Article • Journal of Clinical Oncology, July 2008, American Society of Clinical Oncology (ASCO)

    Laia Pare

  57. Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes

    Article • Clinical Cancer Research, March 2008, American Association for Cancer Research (AACR)

    Laia Pare

  58. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?

    Article • The Pharmacogenomics Journal, August 2007, Springer Science + Business Media

    Laia Pare

  59. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy

    Article • Anti-Cancer Drugs, August 2007, Wolters Kluwer Health

    Laia Pare